Lazure, Patrice
Sireci, Anthony
Subbiah, Vivek
Murray, Suzanne
Grohé, Christian
Sherman, Steven I.
Kelly, Elizabeth
Bubach, Patrick
Péloquin, Sophie
Article History
Received: 2 November 2022
Accepted: 25 May 2023
First Online: 5 June 2023
Declarations
:
: This study was granted approval by an independent ethics review board, VERITAS IRB, Montreal, QC, Canada (IRB Tracking Number: 16454–09:29:058–09-2020; Study Number: GB-18–027). All methods were carried out in accordance with relevant guidelines and regulations. All participants provided informed consent before taking part in the study.
: Not applicable (no individual person’s data, image or video are included in this article).
: Co-authors PL, and SP are employees of AXDEV Group Inc. VS is an Andrew Sabin Family Foundation Fellow at The University of Texas MD Anderson Cancer Center. VS acknowledges support of The Jacquelyn A. Brady Fund. VS is supported by NIH grant R01CA242845. MD Anderson Cancer Center Department of Investigational Cancer Therapeutics is supported by the Cancer Prevention and Research Institute of Texas (RP1100584), the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (1U01 CA180964), NCATS Grant UL1 TR000371 (Center for Clinical and Translational Sciences), and the MD Anderson Cancer Center Support Grant (P30 CA016672), all outside the submitted work. VS reports grants from Eli Lilly/LOXO Oncology, Blueprint Medicines Corporation, Turning Point Therapeutics, Boston Pharmaceuticals; and grants from Helsinn Pharmaceuticals during the conduct of the study; in addition, VS reports a grant and advisory board/consultant position with Eli Lilly/Loxo Oncology during the conduct of the study; research grants from Roche/Genentech, Bayer, GlaxoSmithKline, Nanocarrier, Vegenics, Celgene, Northwest Biotherapeutics, Berghealth, Incyte, Fujifilm, D3, Pfizer, Multivir, Amgen, Abbvie, Alfa-sigma, Agensys, Boston Biomedical, Idera Pharma, Inhibrx, Exelixis, Blueprint Medicines, Altum, Dragonfly Therapeutics, Takeda, National Comprehensive Cancer Network, NCI-CTEP, University of Texas MD Anderson Cancer Center, Turning Point Therapeutics, Boston Pharmaceuticals, Novartis, Pharmamar, Medimmune; an advisory board/consultant position with Helsinn, Incyte, QED Pharma, Daiichi-Sankyo, Signant Health, Novartis, Relay therapeutics, Roche, Medimmune; travel funds from Pharmamar, Incyte, ASCO, ESMO; other support from Medscape. AS, EK and PB are employees of Eli Lilly. SM is CEO and Founder of AXDEV Group Inc., AXDEV Global Inc. and AXDEV Europe GmbH. CG has no competing interests to report. Outside submitted work, SIS reports a grant from Exelixis and advisory board membership with Exelixis and Eisai during the course of this study.